128 related articles for article (PubMed ID: 20224307)
21. Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
Brothers C; Cutrell A; Scott T; Hernandez J; Moult A
Int J Clin Pract; 2006 May; 60(5):611-2; author reply 612. PubMed ID: 16700867
[No Abstract] [Full Text] [Related]
22. Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice?
Barber TJ; Marett B; Waldron S; Portsmouth S; Mackie NE; Weston R; Winston A
AIDS; 2007 Aug; 21(13):1823-4. PubMed ID: 17690585
[TBL] [Abstract][Full Text] [Related]
23. Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects.
Bongiovanni M; Fausto A; Cicconi P; Aliprandi A; Cornalba G; Bini T; Sardanelli F; D'Arminio Monforte A
J Antimicrob Chemother; 2006 Aug; 58(2):485-6. PubMed ID: 16751202
[No Abstract] [Full Text] [Related]
24. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
25. Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors.
Boffito M; Marietti G; Audagnotto S; Raiter R; Di Perri G
Clin Infect Dis; 2002 Feb; 34(4):558-9. PubMed ID: 11797190
[No Abstract] [Full Text] [Related]
26. [New variations in highly active antiretroviral therapy. Simple combination as a promising option].
MMW Fortschr Med; 2000 Mar; 142 Suppl 1():50-2. PubMed ID: 10863312
[No Abstract] [Full Text] [Related]
27. Cardiovascular risks of antiretroviral therapy.
Stein JH
N Engl J Med; 2007 Apr; 356(17):1773-5. PubMed ID: 17460232
[No Abstract] [Full Text] [Related]
28. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
Waters LJ; Mandalia S; Gazzard B; Nelson M
AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
[TBL] [Abstract][Full Text] [Related]
29. Report from the 15th Retrovirus Conference. Is abacavir therapy associated with MI risk?
Hicks CB
AIDS Clin Care; 2008 Apr; 20(4):29. PubMed ID: 19266668
[No Abstract] [Full Text] [Related]
30. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again.
Sax PE
J Watch AIDS Clin Care; 2009 Oct; 21(10):81. PubMed ID: 20458812
[No Abstract] [Full Text] [Related]
31. Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient.
Soler Palacin P; Aramburo A; Moraga FA; Cabañas MJ; Figueras C
Pediatr Infect Dis J; 2006 Apr; 25(4):382. PubMed ID: 16568000
[No Abstract] [Full Text] [Related]
32. [Also consider cardiovascular risk. Every HIV patient "his" HAART].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():58-60. PubMed ID: 19031565
[No Abstract] [Full Text] [Related]
33. Screening for abacavir hypersensitivity.
Deresinski S
AIDS Alert; 2007 Dec; 22(12):140-1. PubMed ID: 18411482
[No Abstract] [Full Text] [Related]
34. Increased cardiovascular risk in patients with human immunodeficiency virus infection under highly active antiretroviral therapy.
Zangerle R; Fuchs D
Am J Cardiol; 2008 Aug; 102(3):373-4. PubMed ID: 18638612
[No Abstract] [Full Text] [Related]
35. Abacavir and the potential risk of myocardial infarction.
Cutrell A; Brothers C; Yeo J; Hernandez J; Lapierre D
Lancet; 2008 Apr; 371(9622):1413. PubMed ID: 18387668
[No Abstract] [Full Text] [Related]
36. Dideoxynucleoside analogues should be used cautiously in patients with hepatic steatosis.
Zeremski M; Talal AH
Clin Infect Dis; 2006 Aug; 43(3):373-6. PubMed ID: 16804854
[No Abstract] [Full Text] [Related]
37. Abacavir and cardiovascular risk: reviewing the evidence.
Costagliola D; Lang S; Mary-Krause M; Boccara F
Curr HIV/AIDS Rep; 2010 Aug; 7(3):127-33. PubMed ID: 20521126
[TBL] [Abstract][Full Text] [Related]
38. An unusual abacavir reaction.
Fox J; Newton P; Daly R; Blume A; Marett B; Greene L; Winston A
AIDS; 2008 Jul; 22(12):1520-2. PubMed ID: 18614878
[No Abstract] [Full Text] [Related]
39. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.
ter Hofstede HJ; Burger DM; Koopmans PP
Neth J Med; 2003 Dec; 61(12):393-403. PubMed ID: 15025414
[No Abstract] [Full Text] [Related]
40. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population.
Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Bingham A; Costagliola D;
AIDS; 2010 May; 24(8):1228-30. PubMed ID: 20400883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
